Mark Pankuch
Research Subjects
Mark Pankuch has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Hanlon
Center for Biostatistics and Health Data Science, Virginia Tech, Roanoke, VA, United States
1 shared publication - Alicia J. Lozano
Department of Statistics Center for Biostatistics and Health Data Science, Virginia Tech Roanoke Virginia USA
1 shared publication - Bee Wah Loo
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
1 shared publication Bharat B. Mittal
Department of Radiation Oncology, Northwest Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
1 shared publicationBirgitte Offersen
Dept of Experimental Clinical Oncology, Dept Oncology, Danish Centre for Particle Therapy, Aarhus University Hospital, Denmark
1 shared publication- Bruce Faddegon
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94115, United States of America
1 shared publication
Latest Publications
- Open Access
- 27 August 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 48, 100847
PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer
- 27 August 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 48, 100847
Open AccessPTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer
- 4 August 2023
- Published by Elsevier in Physica Medica
- Vol. 112, 102649
Dosimetric evaluation of high-Z inhomogeneity with modern algorithms: A collaborative study
- 4 August 2023
- Published by Elsevier in Physica Medica
- Vol. 112, 102649
Dosimetric evaluation of high-Z inhomogeneity with modern algorithms: A collaborative study
- 25 February 2022
- Published by Elsevier in Physica Medica
- Vol. 94, S45-S46
FLASH Modalities Track (Oral Presentations) 3D HIGH SPEED RF BEAM SCANNER FOR HADRON THERAPY OF CANCER
- 25 February 2022
- Published by Elsevier in Physica Medica
- Vol. 94, S45-S46
FLASH Modalities Track (Oral Presentations) 3D HIGH SPEED RF BEAM SCANNER FOR HADRON THERAPY OF CANCER
- 12 April 2021
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 44 (6) , 269-274
Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry
Purpose: As patients with mediastinal lymphoma are typically young with curable disease, advanced radiation techniques such as proton therapy are often considered to minimize subacute and late toxicity. However, it is unclear which mediastinal lymphoma patients are treated with proton therapy. Within a prospective, multi-institutional proton registry, we characterized mediastinal lymphoma patients treated with proton therapy and assessed concordance with consensus recommendations published in 2018 by the International Lymphoma Radiation Oncology Group (ILROG). Methods: Eligible patients included those with lymphoma of the mediastinum treated exclusively with proton therapy for whom digital imaging and communications in medicine (DICOM) treatment data were available for review. Given the challenge with reliably visualizing the left mainstem coronary artery, the inferior-most aspect of the left pulmonary artery (PA) was used as a surrogate. Extent of disease was characterized as upper mediastinum (above level of left PA), middle mediastinum (below left PA but at or above level of T8), or low mediastinum (below T8). Results: Between November 2012 and April 2019, 56 patients were treated and met inclusion criteria. Patients treated with proton therapy were young (median, 24 y; range: 12 to 88), with over half being female (55%). Patients were most commonly treated at initial diagnosis (86%) and had Hodgkin lymphoma (79%). Most patients (96%) had mediastinal disease that extended down to the level of the heart: 48% had middle and 48% had low mediastinal involvement. Nearly all patients (96%) met the ILROG consensus recommendations: 95% had lower mediastinal disease, 46% were young females, and 9% were heavily pretreated. Heart (mean) and lung dose (mean, V5, V20) were significantly associated with lowest extent of mediastinal disease. Conclusions: Mediastinal lymphoma patients treated with proton therapy are typically young with lower mediastinal involvement. Within a prospective, multi-institutional proton registry, nearly all treated patients fit the ILROG consensus recommendations regarding which mediastinal lymphoma patients may most benefit from proton therapy.
- 12 April 2021
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 44 (6) , 269-274
Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry
Purpose: As patients with mediastinal lymphoma are typically young with curable disease, advanced radiation techniques such as proton therapy are often considered to minimize subacute and late toxicity. However, it is unclear which mediastinal lymphoma patients are treated with proton therapy. Within a prospective, multi-institutional proton registry, we characterized mediastinal lymphoma patients treated with proton therapy and assessed concordance with consensus recommendations published in 2018 by the International Lymphoma Radiation Oncology Group (ILROG). Methods: Eligible patients included those with lymphoma of the mediastinum treated exclusively with proton therapy for whom digital imaging and communications in medicine (DICOM) treatment data were available for review. Given the challenge with reliably visualizing the left mainstem coronary artery, the inferior-most aspect of the left pulmonary artery (PA) was used as a surrogate. Extent of disease was characterized as upper mediastinum (above level of left PA), middle mediastinum (below left PA but at or above level of T8), or low mediastinum (below T8). Results: Between November 2012 and April 2019, 56 patients were treated and met inclusion criteria. Patients treated with proton therapy were young (median, 24 y; range: 12 to 88), with over half being female (55%). Patients were most commonly treated at initial diagnosis (86%) and had Hodgkin lymphoma (79%). Most patients (96%) had mediastinal disease that extended down to the level of the heart: 48% had middle and 48% had low mediastinal involvement. Nearly all patients (96%) met the ILROG consensus recommendations: 95% had lower mediastinal disease, 46% were young females, and 9% were heavily pretreated. Heart (mean) and lung dose (mean, V5, V20) were significantly associated with lowest extent of mediastinal disease. Conclusions: Mediastinal lymphoma patients treated with proton therapy are typically young with lower mediastinal involvement. Within a prospective, multi-institutional proton registry, nearly all treated patients fit the ILROG consensus recommendations regarding which mediastinal lymphoma patients may most benefit from proton therapy.
- 16 September 2016
- Published by Springer Nature
- p. 119-144
Techniques for Proton Radiation